Employees: 64
Size Hanx Biopharmaceuticals (Wuhan) (3378.HK) is a Hong Kong Health Care company (Biotechnology) with a market value of $409M, the 801st largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$22.00 on 18 Nov 2026.
Performance Over six months the shares fell 23.5%, against -22.0% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 10th lowest of 21 in its peer set.
Capital Return on invested capital runs 48.6 points below its cost of capital (5.6% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$0 | HK$0 | HK$0 | HK$0 | HK$0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | -HK$7.84M | -HK$6.94M | -HK$5.94M | -HK$1.15M | -HK$1.01M |
| EBITDA | -HK$152M | -HK$135M | -HK$125M | -HK$69.6M | -HK$86.8M |
| Net income | -HK$146M | -HK$142M | -HK$126M | -HK$84.0M | -HK$33.0M |
| Free cash flow | -HK$94.2M | -HK$114M | -HK$117M | -HK$57.6M | -HK$53.4M |
| Capital expenditure | HK$460,289 | HK$2.11M | HK$6.73M | HK$5.28M | HK$998,912 |
| Total debt | n/a | HK$62.2M | HK$153M | HK$16.5M | HK$459,201 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 3378.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -19.2% | -11.3% | 5th lowest of 21 |
| 6-month return | -23.5% | -22.0% | 10th lowest of 21 |
| Distance from 52-week high | -34.9% | -41.5% | 5th highest of 21 |
| ROIC minus cost of capital | -48.6 pp | -7.4 pp | 3rd lowest of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Hanx Biopharmaceuticals (Wuhan) 3378.HK | Hong Kong | $409M | -24% | n/a | n/a | n/a | n/a | n/a |
| Edding Genor 6998.HK | Hong Kong | $410M | -35% | +1,418% | 26% | 1.0× | -15.3% | +197.3% |
| Shanghai Obio Technology (Group) 688238.SS | China | $414M | -5% | +20% | -79% | 10.3× | n/a | n/a |
| Jacobio Pharmaceuticals 1167.HK | Hong Kong | $404M | -24% | +286% | 68% | 1.9× | -18.8% | -36.1% |
| Eupraxia Pharmaceuticals EPRX.TO | Canada | $416M | +1% | n/a | n/a | n/a | n/a | n/a |
| Shanghai Serum Bio-Technology 688163.SS | China | $416M | -34% | -1% | 26% | 10.6× | n/a | n/a |
| G2GBIO 456160.KS | South Korea | $416M | -53% | -45% | -2,884% | 908.6× | n/a | n/a |
| Shanghai Shen Lian Biomedical 688098.SS | China | $402M | -22% | -17% | -16% | 10.9× | n/a | n/a |
| Candel Therapeutics CADL | United States | $417M | -31% | n/a | n/a | n/a | n/a | n/a |
| Rznomics 476830.KS | South Korea | $418M | -76% | -65% | -1,112% | 215.1× | n/a | n/a |
| Shanghai ZJ Bio-Tech 688317.SS | China | $422M | -22% | -10% | -72% | 2.9× | 4.0% | -62.3% |
| Beijing Luzhu Biotechnology 2480.HK | Hong Kong | $396M | -33% | n/a | n/a | n/a | n/a | n/a |
| Wuhan Hiteck Biological Pharma 300683.SZ | China | $395M | -41% | -30% | -27% | 5.2× | n/a | n/a |
| Medigen Vaccine Biologics 6547.TWO | Taiwan | $424M | -8% | +44% | -5% | 14.6× | n/a | n/a |
| Ever Supreme Bio Technology 6712.TWO | Taiwan | $427M | +11% | +13% | 47% | 12.3× | 5.3% | +70.5% |
| Qyuns Therapeutics 2509.HK | Hong Kong | $428M | -11% | +230% | 56% | 2.6× | -19.5% | n/a |
| Beijing Kawin Technology Share-Holding 688687.SS | China | $391M | -20% | +6% | -2% | 1.7× | 36.6% | +8.9% |
| Prothena PRTA | United States | $429M | -11% | +347% | -73% | 3.1× | n/a | n/a |
| Polynovo PNV.AX | Australia | $388M | -34% | +13% | 5% | 3.9× | 51.9% | +37.6% |
| Hubei Goto Biopharm 300966.SZ | China | $386M | -16% | +6% | -10% | 6.0× | n/a | n/a |
| Scinopharm Taiwan 1789.TW | Taiwan | $435M | -2% | -5% | -4% | 4.0× | 2.1% | +0.5% |